Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress
AbstractWith the rapidly spreading resistance of Plasmodium falciparum to available non-artemisinin antimalarial drugs, new and novel pharmaceuticals are needed. ARCO® is a new generation ACT, one of several artemisinin-based combinations developed in China to counter antimalarial drug resistance. ARCO® is a derivative of two independently developed antimalarials, artemisinin and naphthoquine phosphate, which were combined to form the artemisinin-naphthoquine combination. Both artemisinin and naphthoquine drugs have proven to be efficacious, safe and well tolerated as monotherapies. The artemisinin-naphthoquine combination offers a novel advantage over existing ACTs: it can be administered as a single oral dose (or a 1-day treatment). Several therapeutic studies conducted recently indicate that a single oral dose administration of artemisinin-naphthoquine combination is equally effective and safe as the 3-day treatment with artemether-lumefantrine combination and other existing ACTs. This would make ARCO® the next generation ACT for the treatment of uncomplicated falciparum malaria.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Hombhanje, F.W.; Huang, Q. Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress. Pharmaceuticals 2010, 3, 3581-3593.
Hombhanje FW, Huang Q. Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress. Pharmaceuticals. 2010; 3(12):3581-3593.Chicago/Turabian Style
Hombhanje, Francis W.; Huang, Qingyun. 2010. "Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress." Pharmaceuticals 3, no. 12: 3581-3593.